A detailed history of Rhumbline Advisers transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 104,376 shares of AKRO stock, worth $5.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
104,376
Previous 107,338 2.76%
Holding current value
$5.4 Million
Previous $2.52 Million 18.9%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$21.45 - $29.34 $63,534 - $86,905
-2,962 Reduced 2.76%
104,376 $2.99 Million
Q2 2024

Aug 01, 2024

BUY
$18.31 - $24.62 $456,651 - $614,022
24,940 Added 30.27%
107,338 $2.52 Million
Q1 2024

May 09, 2024

BUY
$17.76 - $31.18 $207,774 - $364,774
11,699 Added 16.55%
82,398 $2.08 Million
Q4 2023

Feb 08, 2024

SELL
$11.38 - $50.33 $967 - $4,278
-85 Reduced 0.12%
70,699 $1.65 Million
Q3 2023

Nov 09, 2023

BUY
$41.19 - $52.25 $395,835 - $502,122
9,610 Added 15.71%
70,784 $3.58 Million
Q2 2023

Aug 08, 2023

BUY
$36.89 - $56.88 $232,517 - $358,514
6,303 Added 11.49%
61,174 $2.86 Million
Q1 2023

May 11, 2023

BUY
$37.27 - $50.24 $117,698 - $158,657
3,158 Added 6.11%
54,871 $2.1 Million
Q4 2022

Feb 14, 2023

BUY
$33.44 - $54.8 $316,074 - $517,969
9,452 Added 22.37%
51,713 $2.83 Million
Q3 2022

Nov 10, 2022

BUY
$10.15 - $34.05 $27,151 - $91,083
2,675 Added 6.76%
42,261 $1.44 Million
Q2 2022

Aug 11, 2022

BUY
$8.0 - $15.01 $105,328 - $197,621
13,166 Added 49.83%
39,586 $374,000
Q1 2022

May 12, 2022

BUY
$12.97 - $22.26 $9,922 - $17,028
765 Added 2.98%
26,420 $375,000
Q4 2021

Feb 10, 2022

SELL
$19.87 - $26.24 $10,849 - $14,327
-546 Reduced 2.08%
25,655 $543,000
Q3 2021

Nov 12, 2021

BUY
$18.65 - $25.46 $21,913 - $29,915
1,175 Added 4.7%
26,201 $586,000
Q2 2021

Aug 05, 2021

BUY
$24.81 - $32.35 $282,238 - $368,013
11,376 Added 83.34%
25,026 $621,000
Q1 2021

May 06, 2021

SELL
$24.04 - $34.19 $18,030 - $25,642
-750 Reduced 5.21%
13,650 $396,000
Q4 2020

Feb 10, 2021

BUY
$25.12 - $29.89 $31,902 - $37,960
1,270 Added 9.67%
14,400 $372,000
Q3 2020

Nov 12, 2020

BUY
$30.79 - $39.92 $51,850 - $67,225
1,684 Added 14.71%
13,130 $404,000
Q2 2020

Aug 13, 2020

BUY
$19.25 - $26.76 $220,335 - $306,294
11,446 New
11,446 $285,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $2.4B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.